Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Solid Tumors
Neuroblastoma

Interventions: Drug: Idasanutlin
Drug: Fludarabine
Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Topotecan
Drug: Cytarabine
Drug: Intrathecal Chemotherapy

First Posted Date: 2019-07-23

Last Posted Date: 2024-12-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT04029688

Locations: 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸
Arnold Palmer Hosp-Children, Orlando, Florida, United States

and more 11 locations

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Phase 1

Terminated

Conditions: Triple Negative Breast Cancer
Multiple Myeloma
Ovarian Cancer
Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer
Fallopian Tube Cancer

Interventions: Biological: CART-TnMUC1
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-07-18

Last Posted Date: 2024-01-24

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 16

Registration Number: NCT04025216

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 7 locations

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Phase 1

Conditions: Juvenile Myelomonocytic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Myeloproliferative Neoplasm

Interventions: Biological: CIML NK
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-07-18

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT04024761

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
B-cell Lymphoma

Interventions: Drug: FT516
Drug: Rituximab
Drug: Obinutuzumab
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: IL-2
Drug: Bendamustine

First Posted Date: 2019-07-17

Last Posted Date: 2023-10-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 72

Registration Number: NCT04023071

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 4 locations

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Bendamustine
Drug: Cyclophosphamide
Biological: Filgrastim-sndz
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2019-07-17

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT04022239

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Alemtuzumab
Drug: Fludarabine
Drug: Melphalan

First Posted Date: 2019-07-15

Last Posted Date: 2024-11-25

Lead Sponsor: Emory University

Target Recruit Count: 43

Registration Number: NCT04018937

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's, Phoenix, Arizona, United States
🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States

and more 12 locations

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Phase 4

Completed

Conditions: Thalassemia Major

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thymoglobulin
Drug: cyclosporine A
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2019-07-05

Last Posted Date: 2024-08-09

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 823

Registration Number: NCT04009525

Locations: 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1

Recruiting

Conditions: Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
CD19 Positive
Refractory Chronic Lymphocytic Leukemia
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Follicular Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Biological: Tocilizumab

First Posted Date: 2019-07-05

Last Posted Date: 2024-11-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT04007029

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Clofarabine
Drug: Fludarabine
Drug: Busulfan
Procedure: Total Body Irradiation (TBI)
Drug: Cyclophosphamide
Drug: Granulocyte Colony-Stimulating Factor
Drug: Tacrolimus
Drug: Cellcept

First Posted Date: 2019-06-28

Last Posted Date: 2023-09-14

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 2

Registration Number: NCT04002115

Locations: 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Refractory Large B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-06-28

Last Posted Date: 2024-02-20

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 27

Registration Number: NCT04002401

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy